Lacosamide
- Generic Name
- Lacosamide
- Brand Names
- Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18N2O3
- CAS Number
- 175481-36-4
- Unique Ingredient Identifier
- 563KS2PQY5
- Background
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...
- Indication
Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Status Epilepticus
- Associated Therapies
- -
A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01530386
- Locations
- 🇺🇸
003, Cleveland, Ohio, United States
🇺🇸005, Little Rock, Arkansas, United States
🇺🇸004, Austin, Texas, United States
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT01484977
- Locations
- 🇺🇸
001, Fresno, California, United States
🇧🇬036, Ruse, Bulgaria
🇫🇷046, Paris, France
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 551
- Registration Number
- NCT01465997
- Locations
- 🇫🇮
205, Helsinki, Finland
🇦🇺105, Clayton, Australia
🇺🇸794, Oklahoma City, Oklahoma, United States
To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 51
- Registration Number
- NCT01450111
Lacosamide in Preventing Seizures in Participants With Malignant Glioma
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT01432171
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- University of Kiel
- Target Recruit Count
- 18
- Registration Number
- NCT01382017
- Locations
- 🇩🇪
Departmenr of Neurology, UKSH Campus Kiel, Kiel, Germany
Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 33
- Registration Number
- NCT01375387
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 11
- Registration Number
- NCT01375374
- Locations
- 🇩🇪
2, Bielefeld, Germany
🇦🇹12, Salzburg, Austria
🇪🇸22, Alcorcon, Spain
Add on Lacosamide Versus High Dose Monotherapy
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT01345058
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
- Conditions
- Interventions
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 888
- Registration Number
- NCT01243177
- Locations
- 🇺🇸
881, Mansfield, Texas, United States
🇩🇪263, Altenburg, Germany
🇩🇪260, Göttingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.